Becker's Healthcare December 3, 2025
The Trump administration introduced plans to lower obesity drug costs for Medicaid and Medicare, but commercial insurance coverage of GLP-1s remains a concern.
“There is some speculation that this initiative will help create downward pressure for drug manufacturers to lower costs for commercial plans,” Bruce Rogen, MD, chief medical officer of the Cleveland Clinic Employee Health Plan and chair of the Cleveland Clinic Quality Alliance, told Becker’s.
Last month, GoodRx Research compiled insights on prescription insurance coverage from Managed Markets Insight and Technology, comparing data, as of November 2024 and August 2025, to assess the coverage landscape for GIPs and GLP-1s.
Here are five things to note:
1. Restrictions, such as prior authorization or step therapy, are pronounced. Over 88%...
Today's Sponsors
Today's Sponsor